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Abstract
Background: An often-used tool to measure adherence to antiretroviral therapy (ART) is the Medication Event
Monitoring System (MEMS), an electronic pill-cap that registers date and time of pill-bottle openings. Despite its
strengths, MEMS-data can be compromised by inaccurate use and acceptability problems due to its design. These
barriers remain, however, to be investigated in resource-limited settings. We evaluated the feasibility and
acceptability of using MEMS-caps to monitor adherence among HIV-infected patients attending a rural clinic in
Tanzania’s Kilimanjaro Region.
Methods: Eligible patients were approached and asked to use the MEMS-caps for three consecutive months.
Thereafter, qualitative, in-depth interviews about the use of MEMS were conducted with the patients. MEMS-data
were used to corroborate the interview results.
Results: Twenty-three of the 24 patients approached agreed to participate. Apart from MEMS-use on travel
occasions, patients reported no barriers regarding MEMS-use. Unexpectedly, the MEMS-bottle design reduced the
patients’ fear for HIV-status disclosure. Patients indicated that having their behavior monitored motivated them to
adhere better. MEMS-data showed that most patients had high levels of adherence and there were no bottle-
openings that could not be accounted for by medication intake. Non-adherence in the days prior to clinic visits
was common and due to the clinic dispensing too few pills.
Conclusion: MEMS-bottle use was readily accepted by patients. Although the MEMS-bottle was used accurately by
most patients, patients need to be more explicitly instructed to continue MEMS-use when travelling. Even HIV-
clinics with sufficient staff and free medication may impose structural adherence barriers by supplying an
insufficient amount of pills.
Background
The UNAIDS report of 2009 estimated the global HIV
prevalence at 33.4 million people, of whom 67% are liv-
ing in Sub-Saharan Africa. Two million people died of
AIDS in 2008 and 70% of these deaths occurred in Sub-
Saharan African countries [1]. According to the World
Health Organization (WHO), the antiretroviral therapy
(ART) coverage was 44% in Sub-Saharan Africa by the
end of 2008 [2]. In Tanzania, the estimated adult HIV
prevalence was 5.7% in 2009 (equivalent to 1.4 million
people), and 96,000 died of AIDS in 2008 [3]. By March
2009, 55.2% of the 425,725 Tanzanian children and
adults in need of ART were receiving it [4].
Scaling up the availability of ART is crucial for redu-
cing mortality and HIV-transmission [5]. ART offers an
opportunity to prolong lives of people living with HIV/
AIDS (PLWHA) and revive societies that have been
affected by the epidemic. While access to ART is vital, it
is equally important to ensure that patients adhere to
the prescribed regimen. High levels of adherence (>90-
95%) are required for long-term viral suppression to
delay progression to AIDS [6]. Suboptimal adherence to
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ART increases the risk of drug resistance development.
The emergence of drug resistance is a serious concern,
especially in settings where the options for second-line
treatment are limited [7]. Therefore, monitoring the
patients’ adherence to ART is a requirement for ade-
quate HIV care provision and research.
The accurate measurement of adherence is a challenge
and at present there is no gold standard [8,9]. A tool
that has been used extensively in developed countries is
the Medication Event Monitoring System (MEMS), a
pill-cap that contains an electronic micro-chip that
records date and time of each bottle-opening. In con-
trast to other adherence measurement tools (such as
self-reports, pill-counts, pharmacy refill data, and thera-
peutic drug monitoring), it combines objective data col-
lection with detailed day-to-day information about
medication intake over long time periods. MEMS-data
have been found to accurately predict clinical outcomes
in the treatment of HIV in a range of studies, and its
use has been described in over 500 peer-reviewed publi-
cations [10,11].
Like the other adherence measurement tools, MEMS-
caps data need to be evaluated for possible bias. Some
suggest that MEMS-data may underestimate adherence
due to suboptimal pill-bottle use (such as ‘pocket dos-
ing’, i.e. removing multiple pills at once for later use) or
overestimate adherence because of bottle-openings unre-
lated to medication intake [10]. Moreover, HIV-infected
patients who fear the disclosure of their HIV-status have
expressed concerns regarding the bulky design of the
MEMS-bottle. This could affect consistent use of
MEMS and the patients’ willingness to participate in
MEMS-research, especially in Sub-Saharan Africa where
HIV-related stigma is highly prevalent [12]. Results from
other studies suggest that monitoring ART adherence
by using MEMS may improve medication intake,
although the only study testing this experimentally
revealed no such patterns [13,14]. In sum, electronic
monitoring provides uniquely detailed and objective
adherence data over long time periods, but the data-
quality can be affected by the patients’ acceptance and
use of the device.
Although the importance of studying adherence to
ART in developing countries is widely acknowledged,
only a few studies report using MEMS-caps to monitor
ART adherence in Sub-Saharan Africa [15,16]. This may
be explained by the perception that MEMS-measure-
ment is not feasible in these settings, or that MEMS-
caps are too expensive to use in resource-limited set-
tings. However, the costs of MEMS-caps seem modest
(30 USD per 100 MEMS-caps for one year of data, 22
USD per 5,000 MEMS-caps for one year of data) when
compared with the costs of clinical measures (e.g., 50
USD for a viral load measure and 25 USD for one CD4
cell count) [13]. Hence, with non-adherence preceding
viral replication and thereby CD4 cell count decline as
well as manifestation of clinical symptoms, electronic
measurement of adherence could be a useful and afford-
able option in research and clinic practice in resource-
limited settings.
Considering its potential usefulness for measuring
adherence to ART, studies are needed that evaluate the
feasibility of MEMS-monitoring in resource-limited set-
tings. The aim of this study was to explore the patients’
perceptions of and experiences with using MEMS-caps
to monitor adherence in northern Tanzania.
Methods
Study site
The study was conducted in a rural ART clinic in the
Kilimanjaro Region in northern Tanzania. The clinic
provides services to about 700 PLWHA (of whom 70%
are on ART) and is attended by 50 PLWHA on an aver-
age clinic day. There are two clinic days per week. Once
in every two weeks on a clinic day, a health education
session is conducted with all patients who are attending
the clinic that day. The session takes about 15 minutes
and is conducted by the clinician and a nurse at the
clinic who provides practical information about adher-
ence such as the importance of adherence and how to
stay healthy in general. This health education session is
usually followed by a discussion during which ART
users ask questions and share their experiences in using
ART.
Inclusion criteria and study procedures
This study covered a three-months period during which
participants were using their ART from MEMS-bottles,
after which semi-structured interviews with the partici-
pants were conducted about their experiences with
using MEMS-bottles. Ethical clearance was sought from
the Tanzanian National Institute for Medical Research
(NIMR) prior to commencement of the study (reference
number: NIMR/HQ/R.8a/Vol.IX/812). Financial support
for this study was obtained from the ‘Innovation founda-
tion health care insurers’ (RVVZ, the Netherlands) and
from the ‘AIDS Foundation’ (the Netherlands).
The eligibility criteria for participation in the study
were: (1) aged 18 years or above; (2) being on ART for
at least 6 months; (3) being a regular client to the clinic
and not a temporary visitor; (4) being willing to partici-
pate in the study. All eligible patients who presented on
one random clinic day were approached for participa-
tion. The researcher (author RL) was introduced to eli-
gible patients by the ART clinician and explained that
the aim of the study was to explore how patients per-
ceive the use of a MEMS-bottle for their antiretroviral
medication. Patients were informed that participation in
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the study was voluntary, that refusal would not affect
their relationship with the healthcare provider, and that
they were free to withdraw from the study at any time.
Interested patients signed a consent form.
Study participants were informed that the MEMS-cap
monitors pill intake behavior. The researcher instructed
the patients as follows: (1) open the MEMS bottle only
when taking medication and close it properly afterwards;
(2) always take medication directly from the MEMS-bot-
tle; (3) keep the MEMS bottle in a secured place out of
reach of children or other people who may open the
bottle; (4) take the MEMS-bottle along on clinic visits.
The study participants were followed for a period of
three months (from mid-June to mid-September 2009).
During this period, participants used their medication
from the MEMS-bottle and took the MEMS-bottle
along for medication refill during their monthly routine
clinic visits. Only antiretroviral drugs were put in the
MEMS bottles (no concomitant medication). At the
clinic, patients handed over the MEMS-bottle to the
data clerk who downloaded the data while the patients
visited the clinician. Patients then picked-up the MEMS-
bottle and proceeded to the dispensing nurse who filled
the bottle with medication, after which patients returned
home. Downloaded MEMS-data were not shared with
study participants to avoid influencing their medication
taking behavior, neither were they viewed by clinicians
to avoid them acting upon the findings.
After three months, the patients were approached for
qualitative, in-depth interviews. Patients were provided
with a small compensation for the inconvenience of
spending extra time at the clinic and to cover their
transport costs.
Data collection and analysis
A pre-tested interview guide with open-ended questions
was used. The guide consisted of three major themes:
(1) the MEMS design (opinions about color, shape and
size); (2) the feasibility of using MEMS (ease of use, sto-
rage of the MEMS-bottle, portability of the bottle on
travel occasions, opinions about the guidelines for cor-
rect use); (3) the impact of MEMS-use on adherence
behavior and disclosure concerns.
All interviews were conducted in a private room at the
ART clinic by three trained interviewers (authors RL,
EM, and DM). Interviews lasted approximately one hour
and were conducted in Kiswahili. All interviews were
audio recorded and transcribed. Tape recordings and
transcripts were used for data analysis, after which the
tape recordings were destroyed as per ethical require-
ments. Transcribed data were coded independently by
two researchers (RL and DM) and analyzed to identify
common descriptive themes, which were then grouped
into clusters.
Since self-reports on proper use of the MEMS-bottle
may be biased by social desirability, misinterpretation of
questions and responses, or memory retrieval problems,
following the interviews we also examined the MEMS-
data of all patients for: (a) patterns of overdosing (more
openings on a day than prescribed) without MEMS-
reports showing that patients ran out of medication
before their next clinic visit (which should be the case if
the overdoses are actual medication intakes and not
curiosity openings); and (b) periods of >3 days during
which the MEMS-cap registered no medication intake
events, which could, apart from non-adherence, also
indicate non-MEMS use. To distinguish between non-
adherence and non-MEMS use, we first examined the
interviews for patients reporting periods of non-MEMS-
use. If patients had missing data but did not report inac-
curate MEMS-use, we retrieved information on whether
patients had collected their medication on time. If
patients collected their medication too late in that per-
iod, the MEMS-data were considered accurate and the
patient as non-adherent. If patients did not report inac-
curate MEMS-use in the interview and were always on
time to collect their medication, they were approached
again and asked what happened in that period.
Results
Patient characteristics
All patients who attended the clinic on June 6th 2009
and met the eligibility criteria (n = 24), were approached
for participation in the study and all agreed. However,
one patient, a long-distance truck driver, withdrew from
the study immediately after consenting because he
judged the use of the MEMS-bottle to be incompatible
with his travelling schedule. Hence, 23 ART users com-
pleted the three-month study period and were
interviewed.
Fourteen (61%) participants were married, three (13%)
were single, one (4%) was divorced, and five (22%) were
widowed. All married participants had disclosed their
HIV status to their spouses. The median age was 44
(interquartile range (IQR): 39-48). The period of ART
use by the time of enrollment ranged from 6 to 48
months. At enrolment, the CD4 cell count was less than
200 cells/μL in one patient (4%), between 201 and 300
cells/μL in six patients (26%), between 301 and 500
cells/μL in ten patients (44%), and above 500 cells/μL in
six patients (26%). The patient characteristics are sum-
marized in Table 1.
Acceptability of MEMS-design
The first indicator of the acceptability of the MEMS-
bottle was the patients’ willingness to participate in this
study and use the MEMS-bottle. As reported, all eligible
patients accepted study participation, but one withdrew
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from the study immediately after consenting. The
majority of participants (21/23) indicated to have no
problem with the color and size of the MEMS-bottle. A
female participant (36 years) narrated: “The shape is
good; it looks like a make-up bottle.” Another female (41
years) stated: “This container looks like a body lotion-it
is not easy for people to know that I am carrying the
pills.” A man of 52 years remarked: “This medication
bottle is better than ordinary pill bottles, its shape and
size are OK.” Another man (30 years) said: “If you put
this bottle on the table, no one will know what it is for.
Its size has no problem, and its color-no problem.”
Common feedback was that the MEMS-bottles, con-
trary to the regular medication bottles, do not have
labels that reveal its content. This was perceived as
highly beneficial. For example, a female of 39 years
remarked: “This container is very good. No one would
immediately know what it is for. The normal pill bottles
are labeled so when someone sees it, it is recognized
quickly.” Another female (41 years) said: “This one is
cool. With the other type, people read it and start bom-
barding you with questions.”
Upon inquiring about what patients think the ideal
shape of a MEMS-bottle would be, two participants pro-
posed that a flat-shaped container would be easier to
carry in one’s pocket. A long-distance truck driver
(male, 50 years) said: “I would prefer a container with a
flat shape like a small mobile phone because it will be
easy to put in the pocket.”
Feasibility of using MEMS according to guidelines
None of the patients reported to have had difficulties
with following the guidelines for accurate MEMS-use: 1]
to put the MEMS-cap on the pill bottle after use and
close it properly, 2] always take all pills from the
MEMS-bottle, and 3] prevent the bottle from being
opened by a family member. Moreover, no one com-
plained about the condition not to open the pill-bottle
between medication intakes. A widower (44 years) said
“I keep it on my table, it’s easy. I have my time for medi-
cation intake, so I open it during that time. On travel
occasions, I move with it.” When asked if a family mem-
ber or child might have opened the MEMS-bottle, most
patients reported to have kept the MEMS-bottle out of
reach from others. A woman (41 years) remarked: “I did
not have any problem whatsoever. I keep it in my bed-
room and put it in a drawer to avoid it being opened by
children. I have no problem with it, the instruction is not
difficult.” One participant (male, 50 years) said: “I hide
my container in my suitcase. I don’t want children or
any other person to open it or ask me about it, this is
my secret.”
Four participants talked about the challenges of always
using all their medication from the MEMS-bottle. These
challenges were mainly related to travelling. The
patients considered it unsafe to travel with the bottle as
they feared that it could be stolen or lost. For example,
a long-distance truck driver (male, 50 years) indicated:
“When I was traveling, I left it at home and took the
medication along. I was afraid the device could be sto-
len.” A female (39 years) confessed: “I left my MEMS-
bottle at home during my travel away from home and I
transferred my pills into an ordinary medication bottle.”
A mason (man, 50 years) said: “I had to travel to Arusha
for construction work for one and a half month. I left my
MEMS-bottle at home and instead transferred my pills
into another bottle. I feared my MEMS-bottle could be
stolen or misplaced at the construction site.”
Impact of MEMS-use on patient behavior
Nearly 75% of patients (17/23) had informed other
family members that they had a new medication con-
tainer. As one of the respondents said: “I have informed
Table 1 Demographic and disease characteristics of
participants who completed the study (N = 23)
Characteristics N (%)
Gender
Female 14 (61%)
Marital status
Married 14 (61%)
Single 3 (13%)
Divorced 1 (4%)
Widowed 5 (22%)
Months on ART
6-12 2 (9%)
12-24 12 (52%)
24-48 9 (39%)
Education level
No formal education 1 (4%)
Some primary education 4 (17%)
Completed primary education 15 (65%)
Secondary Education 3 (13%)
Occupation
Subsistence farming 10 (44%)
Monthly Salaried work 4 (17%)
Days wage/Occasional work 5 (22%)
Petty business 4 (17%)
Distance to the clinic
Less than 3km/walking distance 16 (70%)
Above 3 km 7 (30%)
CD4 cell count at baseline (cells/μL)
>501 1 (4%)
301 - 500 6 (26%)
201 - 300 10 (43%)
<200 6 (26%)
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my family and children that this bottle records pill tak-
ing behavior every time you open, so I strictly forbid
them to touch it because it will be revealed when false
openings are done to the pills bottle.” All participants
who had told their family members about the MEMS-
bottle said that their family members became more sup-
portive in reminding them to take the medication. One
participant (female 45 years) said: “Because my family
members don’t want me to have a bad record on my
medication, they are very supportive in reminding me
about the time to take pills.”
On the question about how patients felt that their
behavior was being monitored by the MEMS-cap, a typi-
cal response was: “I have no problem with that.” A
female (45 years) answered: “That is very good because
it motivates me to remember to take pills.” A man (30
years) remarked: “I have become more conscious in tak-
ing medication. I am now more systematic and I don’t
forget to take my pills because I know that I am been
monitored. With other containers I could take pills any
time and skip taking pills at will.” Similarly, another
man (45 years) said: “Because I know that I am being
recorded, I make every effort to take my medication as
prescribed.” A women (45 years) stated: “In the past I
used to skip pills even for about 20 days, sometimes I
found myself with two containers full of pills, but with
this new container, I don’t skip a day.”
Corroborating interview responses with MEMS-data
Examination of the MEMS-reports revealed that there
was no evidence of systematic overdosing by any of the
patients. Bottles were typically opened twice a day at
regular intervals. Sporadically, MEMS-bottles were
opened three times a day instead of two. This was
usually on clinic visit days when the bottle was refilled.
Hence, these data confirm patients’ reports that they
only opened the pill-bottle for medication intake.
There were six patients whose MEMS-data showed
periods of more than three days of missed medication
(observed range was 12 to 71 days). Two of these
patients reported during the initial interviews that they
had left the MEMS-bottle at home when travelling, fear-
ing that it might be stolen. Hence, they were not consid-
ered as non-adherent, but as not using the MEMS-cap.
Two of the four remaining patients, who reported in the
initial interviews to have always used the MEMS-cap as
prescribed, showed up too late for collecting their medi-
cation in that period. Their missing MEMS-data was
therefore considered to accurately describe their medica-
tion intake (i.e., non-adherence). Of the two remaining
patients, who did not self-report inaccurate MEMS-use
and were on time for collecting their medication, one
could be re-contacted to explain the data. This patient
reported to have left the MEMS-bottle at home when
travelling for a period of six weeks. The non-monitored
period was indeed 6 weeks, and this was thus considered
to be non-MEMS-use rather than non-adherence.
Hence, the MEMS-caps seemed to have been used accu-
rately by all patients, except by three patients who did
not use it during long-distance travels.
MEMS-adherence scores
The interviews suggest that patients were, on average,
highly adherent. Moreover, they suggest that patients
changed their medication intake behavior because they
were being monitored, an effect that has also been
recognized in the Western literature. However, this
monitoring effect is expected to reduce over time [16].
As a final step, we therefore explored the patients’
monthly adherence scores, namely the percentage of
doses taken (taking adherence) and the percentage of
doses taken within a 9-15 hour interval (timing adher-
ence), and explored whether adherence decreased over
time also in this study. For the three patients who tra-
velled and used their medication from another bottle,
their period of non-MEMS-use was set to ‘missing’.
Monthly adherence scores were only computed for
these three patients if they provided at least two weeks
of continuous MEMS-data.
The adherence scores are summarized in Table 2 and
reveal that adherence levels were fairly high and
declined somewhat over time. Seventy-four percent (17/
23) of the patients took more than 95% of their medica-
tion during the first month, 63% (14/22) in month 2
and 62% (13/21) in month 3. Wilcoxon’s Signed Rank
tests revealed that for taking and timing adherence there
was a statistically significant decrease in adherence
between month 1 and 3 (both p < 0.05), but not
between month 1 and 2, or 2 and 3.
One additional finding was that MEMS-data fre-
quently revealed 3-5 days of non-adherence before a
clinic visit. Upon exploring the cause of this pattern, it
became clear that whereas the time between two conse-
cutive visits in this clinic ranges from 30 to 35 days,
Table 2 Adherence scores per month
1st month
(n = 23)
2nd month
(n = 22)
3rd month
(n = 21)
Taking
adherence*
Mean (SD) 97.4 (4.7) 95.9 (5.78) 85.0 (26.8)
Median
(IQR)
98.2 (4.6) 96.4 (5.4) 98.2 (18.8)
Timing
adherence^
Mean (SD) 94.2 (6.8) 92.6 (6.1) 82.1 (26.4)
Median
(IQR)
96.4 (4.6) 92.9 (6.3) 96.7 (20.5)
* Percentage of prescribed doses taken.
^ Percentage of doses taken within 12 ± 3 hours
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patients were only provided with medication for 30 days.
Hence, even the most motivated patients could not
always be fully adherent due to mismanagement at the
clinic level.
Discussion
This study explored the feasibility and acceptability of
using MEMS-bottles to monitor adherence to ART in
Tanzania’s Kilimanjaro Region. Twenty-three patients
on ART used a MEMS-bottle during three consecutive
months. After this period, in-depth interviews were con-
ducted with the participants. Overall, patients perceived
MEMS-bottles as simple and acceptable for use. The
absence of a label on the bottle was perceived as an
advantage to the ordinary pill-bottles and, unexpectedly,
reduced fear for HIV-status disclosure. The majority of
patients stated that the use of MEMS-caps had
improved their adherence because of increased family
support and the knowledge that the MEMS-bottle was
monitoring their behavior. This is in line with findings
by Wendel et al. [17].
Whereas we found that the MEMS-bottle was readily
accepted by patients on ART, other studies found that
some patients, especially those who prefer not to disclose
their HIV-status, do not like the white, bulky appearance
of the MEMS for privacy concerns [18-20]. The high
acceptability of MEMS-use by patients in the current
study is particularly remarkable because fears of disclosure
of one’s HIV-status and consecutive stigmatization are
widely present in Tanzania and patients prefer to carry
their medication as discretely as possible [21,22]. It turned
out that the MEMS-design facilitated just that, with the
absence of a medication label and the perception that the
MEMS-bottle looks like a package of common products in
this region, such as lotion or shampoo bottles.
The main barrier to using MEMS was on travel occa-
sions. Three patients indicated to have left the MEMS
bottle at home during travelling because of fears that it
might be lost or stolen. This fear of losing the MEMS
bottle on travel occasions was because patients per-
ceived the MEMS-cap as a valuable device that could be
stolen. This finding indicates the need of stressing
patients that using the medication from the MEMS-caps
when travelling is important and that the risk of it being
stolen is acceptable and the responsibility of the
researcher. This is especially important because adhering
to the medication may be more challenging when
travelling.
It has been suggested that MEMS monitoring can be
perceived as intrusive or patronizing [20]. Patients in the
present study perceived the monitoring of their adher-
ence behavior as an advantage; they reported that their
adherence had improved due to MEMS-monitoring.
Most participants explicitly said that they paid more
attention to taking their medication on the correct time
because they were aware that their adherence behavior
was monitored. Some patients admitted that they had
been skipping medication intake for weeks in a row
prior to starting to use the MEMS-bottle, but not any-
more since MEMS-use. Adherence rates were indeed
high, especially during the first month of monitoring.
However, the levels of adherence tended to decrease
after the first month of the study and then stabilized,
suggesting that patients returned to their usual adher-
ence behavior. This pattern has also been observed in
other studies [23,24].
Examining the MEMS-data in order to determine per-
iods of non-adherence or non-MEM-use, patterns of
missed doses were found prior to clinic visits, because
too few pills were being given to patients to bridge time
between consecutive visits. Upon discussing the poten-
tial health consequences of this malpractice, the health-
care providers and dispensing nurse, acknowledging the
necessity of a sufficient supply of medication, now pro-
vide patients with enough medication (including a buffer
supply in case a patient is not able to visit the clinic on
the appointed day).
This study showed that MEMS-devices have potential
application in adherence research and monitoring of
adherence in clinical practice in resource-limited set-
tings. Although attention has to be paid to accurate
MEMS-use, both at the time of instruction as well as at
the moment of data interpretation, we did not observe
some of the typical hurdles related to MEMS-use in
resource-rich settings. For example, patients did not
experience problems with the MEMS-design. In the
absence of financial resources for regular viral load or
CD4 testing, (intermittent) monitoring of adherence
with the MEMS-cap may be possible and thus provide
clinicians with valuable information to support the
patients’ medical treatment and medication adherence.
This study had some limitations. First, the sample size
was small and the study was conducted in a single
clinic, which limits external validity of the findings.
However, the aim of the study was to explore the feasi-
bility and acceptability of the MEMS-cap through quali-
tative procedures. Second, patients may not have
understood well enough that their adherence data would
not be shared with their doctor. The expectation that
the doctor would act upon detection of non-adherence,
might explain part of the intervention effect of MEMS-
use, as described above. Third, the average adherence of
patients with long periods of non-MEMS use should be
interpreted with caution, since it cannot be verified
whether medication was taken as prescribed in that
period.
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Conclusions
This study suggests that the use of MEMS in a
resource-limited, rural setting is feasible and acceptable
to patients, and a potentially reliable source of informa-
tion in settings where viral loads are not readily avail-
able. Special attention should be paid, though, to
instructing patients about using the MEMS-cap while
travelling. Moreover, researchers and clinicians are
advised to develop procedures to verify whether missing
MEMS-data was due to non-adherence or non-MEMS-
use. Finally, although beneficial in clinical practice or
adherence supporting interventions, the reported effects
of MEMS-monitoring on adherence could introduce
noise and threaten outcomes in research. Guaranteeing
the patients’ anonymity in data processing and analysis,
and incorporating a period during which patients can
get used to the MEMS-bottle are therefore advised.
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